Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling

Luodan Zhang; Fa Zeng; Minmin Jiang; Maozhen Han; Binbin Huang

doi:10.3389/fcell.2022.1005681

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling

Front Cell Dev Biol. 2022 Nov 3:10:1005681. doi: 10.3389/fcell.2022.1005681. eCollection 2022.

Authors

Luodan Zhang¹, Fa Zeng², Minmin Jiang^{3

4}, Maozhen Han⁵, Binbin Huang⁴

Affiliations

¹ Department of Nephrology, Anhui Provincial Children's Hospital, Children's Hospital of Anhui Medical University, Hefei, Anhui, China.
² Shenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China.
³ Department of Occupational Health and Environmental Health, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
⁴ Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, MOE Key Laboratory of Population Health Across Life Cycle, NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Provincial Key Laboratory of Population Health and Aristogenics, Hefei, Anhui, China.
⁵ College of Life Science, Anhui Medical University, Hefei, Anhui, China.

Abstract

Endocrine and metabolic diseases show increasing incidence and high treatment costs worldwide. Due to the complexity of their etiology and mechanism, therapeutic strategies are still lacking. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, appears to be a potential candidate for the treatment of these diseases. Studies based on clinical analysis and rodent animal models reveal the roles of OPG in various endocrine and metabolic processes or disorders, such as bone remodeling, vascular calcification, and β-cell proliferation, through the receptor activator of nuclear factor kappa-B ligand (RANKL) and the receptor activator of NF-κB (RANK). Thus, in this review, we mainly focus on relevant diseases, including osteoporosis, cardiovascular disease (CVD), diabetes, and gestational diabetes mellitus (GDM), to summarize the effects of the RANKL/RANK/OPG system in endocrine and metabolic tissues and diseases, thereby providing a comprehensive insight into OPG as a potential drug for endocrine and metabolic diseases.

Keywords: cardiovascular disease; gestational diabetes mellitus; nuclear factor kappa-B ligand; osteoporosis; osteoprotegerin; receptor activator of NF-κB.

Publication types

Review